Irinotecan
Recurrent Childhood Pineoblastoma
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Pineoblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM St. Jude Children's Research Hospital | Phase 3 | BB |
Cediranib Pediatric Brain Tumor Consortium | Phase 1 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 1 | CCC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CCC |
Vorinostat National Cancer Institute (NCI) | Phase 1 | CCC |
View all 23 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →